undamentalytics Newsletter
Sign in

Neuphoria Therapeutics Inc. income statement

In fiscal 2026, Neuphoria Therapeutics Inc. reported revenue of $1.2m, down 92.5% on the year before, operating income of −$16.5m (a -1401.1% margin) and net income of −$13.5m, or −$3.06 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2025Jun 20252026Jun 2026
Revenue161
Research and development9—
General and administrative87
Operating income−1−16
Income before tax−1−14
Income tax−0−0
Net income−0−13
Diluted EPS−$0.23−$3.06
Diluted shares (average)2m4m
EBITDA−0−16

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Neuphoria Therapeutics Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Neuphoria Therapeutics Inc.